Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24

Profound Medical (PROF) is a micro/small-cap commercial-stage medtech company announcing a pre-catalyst event: first clinical outcomes from the CAPTAIN trial on March 13, followed by ROTH conference participation. The fact that management is proactively scheduling an investor call to discuss results carries a mild positive signaling effect—companies rarely telegraph negative data with dedicated investor events. However, this remains a binary clinical data readout in a thinly traded name (avg daily volume likely under 100K shares), meaning position sizing is critical. The CAPTAIN trial is a Level 1 post-market comparative study, which is less binary than pre-approval trials but still pivotal for driving clinical adoption, reimbursement expansion, and potential partnership interest. The ROTH conference on March 22-24 provides a secondary catalyst for broader small-cap investor exposure. ⚡ DEEP OPUS: Scale into a small position between now and March 12, avoiding chasing any pre-announcement run-up. Consider buying 50% of target position immediately and the remaining 50% only after confirming positive March 13 data, accepting a higher cost basis for reduced binary risk. | TP:22% SL:15% | 2-4 weeks (through ROTH conference March 24) | Risk:HIGH - Binary clinical data event in a thinly traded micro-cap with wide bid-ask spreads. Negative or ambiguous CAPTAIN trial results could trigger 25-40% downside. Liquidity risk is significant; exiting a position quickly during adverse moves may be difficult. Single-product concentration risk amplifies the binary nature of this catalyst. | Sizing:CONSERVATIVE